AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug

• Jefferies analyst Michael Leuchten maintained a ‘Buy’ rating and $243 price target on AstraZeneca following the committee vote on camizestrant.
• This suggests that the FDA is now unlikely to approve the drug in this setting, the analyst noted.
• However, "this should come as no surprise," the analyst said.

Shares of AstraZeneca (AZN) closed up 1% on Thursday after Wall Street dismissed the negative vote on the company’s breast cancer drug as unsurprising.

The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 6-3 against a favorable benefit-risk profile for AstraZeneca’s camizestrant in combination with other drugs for the treatment of certain patients with advanced breast cancer, AstraZeneca said.

The FDA accepted AstraZeneca's application for camizestrant in July 2025 based on the results of a late-stage trial, which showed a 56% reduction in the risk of disease progression or death with the camizestrant combination versus standard-of-care treatment.

The FDA does not have to abide by the committee’s opinion, but takes its advice into consideration, the company noted. AstraZeneca’s application continues to be under the agency’s review.  

Regulatory applications for camizestrant in this setting are also under review in the EU, Japan, and several other countries, AstraZeneca noted.

Analyst Chimes In

Jefferies analyst Michael Leuchten maintained a ‘Buy’ rating and $243 price target on AstraZeneca following the committee vote on camizestrant. This suggests that the FDA is now unlikely to approve the drug in this setting, the analyst noted, while adding that "this should come as no surprise" after the publication of the prior briefing documents.

The analyst noted that the trial in question is not part of the firm's ‘Buy’ thesis, and the trial accounts for "only a small part of the $80B 2030 sales target." The company reported total revenue of $58.74 billion in 2025.

Jefferies concluded that any weakness following this news "presents a buying opportunity."

How Did AZN Retail Traders React?

On Stocktwits, retail sentiment around AZN rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

AZN stock has gained 29% over the past 12 months. 

Read More: RIVN Rallies After-Hours On Q1 Beat While Investors Pile Into R2 Story

For updates and corrections, email newsroom[at]stocktwits[dot]com.